TY - JOUR
T1 - Pentostatin (Nipent) and high-dose cycloposphamide for the treatment of refractory autoimmune disorders
AU - Goodman, M.
PY - 2000/7/12
Y1 - 2000/7/12
N2 - Autoimmune rheumatologic diseases has a wide range of clinical expression that occasionaly can be disabling. Patients with visceral organ involvement are exposed to significant morbidity and mortality if effective therapy is not forthcoming. The mainstay of therapy has been immunosuppression. However, some patients fail to respond to conventional doses of corticosteriods, methotrexate, or cyclophosphamide, and new approaches are needed for these patients. One new approach involves the use of intensified immunosuppression by combining cyclophosphamide with purine nucleoside analogs, including the adenosine deaminase inhibitor pentostatin (Nipent; Super Gen, San Ramon, CA). Copyright (C) 2000 by W.B. Saunders Company.
AB - Autoimmune rheumatologic diseases has a wide range of clinical expression that occasionaly can be disabling. Patients with visceral organ involvement are exposed to significant morbidity and mortality if effective therapy is not forthcoming. The mainstay of therapy has been immunosuppression. However, some patients fail to respond to conventional doses of corticosteriods, methotrexate, or cyclophosphamide, and new approaches are needed for these patients. One new approach involves the use of intensified immunosuppression by combining cyclophosphamide with purine nucleoside analogs, including the adenosine deaminase inhibitor pentostatin (Nipent; Super Gen, San Ramon, CA). Copyright (C) 2000 by W.B. Saunders Company.
UR - http://www.scopus.com/inward/record.url?scp=0033920811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033920811&partnerID=8YFLogxK
M3 - Article
C2 - 10877056
AN - SCOPUS:0033920811
VL - 27
SP - 67
EP - 71
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 3 SUPPL. 5
ER -